<?xml version="1.0" ?>
<TEI xmlns="http://www.tei-c.org/ns/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" 
 xmlns:mml="http://www.w3.org/1998/Math/MathML">
	<teiHeader>
		<fileDesc xml:id="f_1"/>
	</teiHeader>
	<text>
		<front/>
		<body/>
		<back>
			<listBibl>
<ref>Asplund K, Ashburner S, Cargill K, Hux M, Lees K, Drummond M, 
et al (2003) Health care resource use and stroke outcome. 
Multinational comparisons within the GAIN International trial. 
Int J Technol Assess Health Care 19(2):267-277</ref>
<ref>Bastian H, Bender R, Ernst AS, Kaiser T, Kirchner H, Kolominsky-
Rabas P, Lange S, Sawicki PT, Weber M (2006) Methoden. Köln: 
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen 
(IQWiG). Report No.: version 2.0</ref>
<ref>Bryan S, Brown J (1998) Extrapolation of cost-effectiveness information to 
local settings. J Health Serv Res Policy 3(2):108-112</ref>
<ref>Bytzer P (1999) Cost-effectiveness of gastroscopy. Ital J Gastroenterol 
Hepatol 31(8):749-760</ref>
<ref>Claxton K, Sculpher M, McCabe C, Briggs A, Akehurst R, Buxton M, 
Brazier J, O'Hagan T (2005) Probabilistic sensitivity analysis for 
NICE technology assessment: not an optional extra. Health Econ 
14(4):339-347</ref>
<ref>Cook JR, Drummond M, Glick H, Heyse JF (2003) Assessing the 
appropriateness of combining economic data from multinational 
clinical trials. Stat Med 22(12):1955-1976</ref>
<ref>Drummond MF, Pang F (2001) Transferability of economic evaluation 
results. In: Drummond MF, McGuire A (eds) Economic 
evaluation in health care: merging theory with practice. Oxford 
University Press, Oxford 
Drummond MF, O'Brien BJ, Stoddart GL, Torrance GW (1997) 
Methods for economic evaluation of health care programmes, 
2nd edn. Oxford University Press, Oxford 
Grieve R, Nixon R, Thompson SG, Normand C (2005) Using 
multilevel models for assessing the variability of multinational 
resource use and cost data. Health Econ 14(2):185-196</ref>
<ref>Halliday RG, Darba J (2003) Cost data assessment in multinational 
economic evaluations: some theory and review of published 
studies. Appl Health Econ Health Policy 2(3):149-155</ref>
<ref>Hay J, Jackson J (1999) Panel 2: methodological issues in conducting 
pharmacoeconomic evaluations-modeling studies. Value Health 
2(2):78-81</ref>
<ref>Heyland DK, Kernerman P, Gafni A, Cook DJ (1996) Economic 
evaluations in the critical care literature: do they help us improve 
the efficiency of our unit? Crit Care Med 24(9):1591-1598</ref>
<ref>Hjelmgren J, Berggren F, Andersson F (2001) Health economic 
guidelines-similarities, differences and some implications. 
Value Health 4(3):225-250</ref>
<ref>Jönsson B, Weinstein MC (1997) Economic evaluation alongside 
multinational clinical trials. Study considerations for GUSTO IIb. 
Int J Technol Assess Health Care 13(1):49-58</ref>
<ref>Kaplan GA, Keil JE (1993) Socioeconomic factors and cardiovascular 
disease: a review of the literature. Circulation 88(4 Pt 1):1973-
1998</ref>
<ref>Koopmanschap MA, Touw KC, Rutten FF (2001) Analysis of costs 
and cost-effectiveness in multinational trials. Health Policy 58 
(2):175-186</ref>
<ref>Manca A, Willan AR (2006) 'Lost in translation': accounting for 
between-country differences in the analysis of multinational cost-
effectiveness data. Pharmacoeconomics 24(11):1101-1119</ref>
<ref>Menzin J, Oster G, Davies L, Drummond MF, Greiner W, Lucioni 
C, Merot JL, Rossi F, vd Schulenburg JG, Souêtre E (1996) A 
multinational economic evaluation of rhDNase in the treat-
ment of cystic fibrosis. Int J Technol Assess Health Care 12 
(1):52-61</ref>
<ref>Moayyedi P (2007) The health economics of Helicobacter pylori 
infection. Best Pract Res Clin Gastroenterol 21(2):347-361</ref>
<ref>O'Brien BJ (1997) A tale of two (or more) cities: geographic 
transferability of pharmacoeconomic data. Am J Manag Care 3 
(Suppl):S33-S39</ref>
<ref>Pinto EM, Willan AR, O'Brien BJ (2005) Cost-effectiveness analysis 
for multinational clinical trials. Stat Med 24(13):1965-1982</ref>
<ref>Reed SD, Anstrom KJ, Bakhai A, Briggs AH, Califf RM, Cohen DJ, 
Drummond MF, Glick HA, Gnanasakthy A, Hlatky MA et al 
(2005) Conducting economic evaluations alongside multinational 
clinical trials: toward a research consensus. Am Heart J 149 
(3):434-443</ref>
<ref>Schöffski O, Graf von der Schulenburg JM (2007) Die Standardisierung 
der Methodik: Guidelines. In: Gesundheitsökonomische Evaluatio-
nen, 3 ed. Spinger, Berlin, pp 471-489</ref>
<ref>Sculpher MJ, Pang FS, Manca A, Drummond MF, Golder S, Urdahl 
H, Davis LM, Eastwood A (2004) Generalisability in economic 
evaluation studies in healthcare: a review and case studies. 
Health Technol Assess 8(49):iii-iv</ref>
<ref>Siebert U (2003) When should decision-analytic modeling be used in 
the economic evaluation of health care? Eur J Health Econ 
4:143-150</ref>
<ref>Thompson SG, Nixon RM, Grieve R (2006) Addressing the issues 
that arise in analysing multicentre cost data, with application to a 
multinational study. J Health Econ 25(6):1015-1028</ref>
<ref>Willan AR, Pinto EM, O'Brien BJ, Kaul P, Goeree R, Lynd L, 
Armstrong PW (2005) Country specific cost comparisons from 
multinational clinical trials using empirical Bayesian shrinkage 
estimation: the Canadian ASSENT-3 economic analysis. Health 
Econ 14(4):327-338</ref>
<ref>Willke RJ, Glick HA, Polsky D, Schulman K (1998) Estimating 
country-specific cost-effectiveness from multinational clinical 
trials. Health Econ 7(6):481-493</ref>
			</listBibl>
		</back>
	</text>
</TEI>
